Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | The future of CAR-T therapy and the role of transplantation within this field

Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, shares some insights into the exciting field of chimeric antigen receptor T-cell (CAR-T) therapy and its role in both malignant and non-malignant indications, such as systemic lupus erythematosus (SLE). Dr Gavriilaki explains the hope to expand the population of patients who can benefit from CAR-T, as well as the physician community, and that this field is constantly developing. To conclude, Dr Gavriilaki mentions the importance of transplantation in hematological malignancies, and the benefit that can be obtained from personalizing both CAR-T and allogeneic transplantation to improve patient outcomes. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Transcript (edited for clarity)

CAR-T is a very exciting field, as we all know, and we will see not only new products, but most importantly, new indications. We are excited not only for the malignant indications, but also for the non-malignant ones like systemic lupus erythematosus or SLE that is presented also in this Congress. And we hope that during this process, we will be able to expand the population that will benefit from CAR-T therapy and also expand the physician community that knows about CAR-T and expand the facilities that will be able to perform the CAR-T therapy...

CAR-T is a very exciting field, as we all know, and we will see not only new products, but most importantly, new indications. We are excited not only for the malignant indications, but also for the non-malignant ones like systemic lupus erythematosus or SLE that is presented also in this Congress. And we hope that during this process, we will be able to expand the population that will benefit from CAR-T therapy and also expand the physician community that knows about CAR-T and expand the facilities that will be able to perform the CAR-T therapy. So this is a very exciting field for all of us and this field is constantly developing.
Regarding the transplantation, we as transplanters feel that transplantation still has a major role in all these indications. We feel that we need to develop personalized algorithms in order to fit in CAR-T and allogeneic transplantation and determine the best available option for each patient at each time. So we think that CAR-T is not an enemy of transplantation, but will help patients get into transplantation with a better status.

Read more...

Disclosures

Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi.
Dr Gavriilaki has received research support from Jazz Pharmaceuticals.